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ABSTRACT In this communication, we report an in-depth structure-based analysis of the human CYP1b1 protein carrying dis-
ease-causing mutations that are discovered in patients suffering from primary congenital glaucoma (PCG). The ‘‘wild-type’’ and
the PCGmutant structures of the human CYP1b1 protein obtained from comparative modeling were subjected to long molecular
dynamics simulations with an intention of studying the possible impact of these mutations on the protein structure and hence its
function. Analysis of time evolution as well as time averaged values of various structural properties—especially of those of the
functionally important regions: the heme binding region, substrate binding region, and substrate access channel—gave some
insights into the possible structural characteristics of the disease mutant and the wild-type forms of the protein. In a nutshell,
compared to the wild-type the core regions in the mutant structures are associated with subtle but signiﬁcant changes, and the
functionally important regions seem to adopt such structures that are not conducive for the wild-type-like functionality.
INTRODUCTION
Primary congenital glaucoma (PCG) is a severe eye disorder
occurring at birth or early childhood (seen up to 3 years) and
is a major cause of blindness in infancy. This disease is char-
acterized by a developmental abnormality of the trabecular
meshwork in the anterior chamber angle of the eye leading to
increased intraocular pressure, which results in optic nerve
damage and permanent loss of vision (1). PCG has been
found to be mainly autosomal recessive in inheritance. The
prevalence of the disease has been reported to vary geo-
graphically, with incidence ratios as low as 1:10,000 in the
West to as high as 1:1,250 among the Slovak gypsies (2).
High incidence ratios have usually been found in populations
that practice inbreeding and consanguinity.
Genetic linkage studies have indicated that PCG is, genet-
ically, a heterogeneous disease, mapping onto at least three
different loci. The ﬁrst locus is GLC3A, located in the region
2p21 of chromosome 2 (3); the second is GLC3B, located
in the region 1p36 of chromosome 1 (4); and the third is
GLC3C, located in the region 14q24.3 on chromosome 14
(5). In the majority of the PCG instances the candidate locus
has been found to be GLC3A, which codes for a cytochrome
p450 protein called CYP1b1.
The human CYP1b1 is a 543 amino acid long protein
made up of three regions: the 53 residue long membrane-
bound N-terminal region, a 10 residue long proline-rich re-
gion called ‘‘the hinge’’, and the 480 residue long cytosolic
globular domain. It is thought that CYP1b1 participates in
the development of the trabecular meshwork of eye, which
serves as a ﬁlter for drainage of anterior chamber ﬂuid (6). To
date, the mechanism or the pathway by which CYP1b1 func-
tions in the development of the trabecular meshwork is not
known. However, it is suspected that CYP1b1 may be in-
volved in the elimination of a metabolite, the presence of
which may have a toxic effect on eye development. It has
also been thought that the protein may be involved in the
generation of a regulatory molecule which controls the ex-
pression of genes involved in the development of the anterior
chamber angle of the eye (7). It is certain that mutations
having deleterious effects on protein function do hamper the
normal development of the trabecular meshwork.
Sequence analyses have so far revealed several mutations
in the CYP1b1 gene, of which some are found only in the
PCG affected individuals (6,8–17). Recently, Panicker and
co-workers (18,19) reported eight mutations in the Indian
PCG patients. Our preliminary study had indicated that some
of these nonsynonymous mutations occur in the conserved
structural regions of the protein (18). It was therefore tempt-
ing to carry out detailed studies to explore the possible im-
pact of these mutations on the protein structure and function.
In this study, the wild-type (WT) and the mutant (MT) struc-
tures corresponding to the eight PCG mutations, A-115P,
M-132R, Q-144P, P-193L, E-229K, S-239R, R-368H, and
G-466D, have been obtained by comparative modeling ap-
proaches. The models were subjected to long molecular dy-
namics (MD) simulations with the intention of studying the
time evolution as well as time averaged values of structural
properties, especially of the functionally important regions
(FIRs). Our investigations have revealed that the MT struc-
tures show differential structural properties during the
simulation period compared to the WT. Very importantly,
Submitted March 22, 2006, and accepted for publication August 21, 2006.
Address reprint requests to Hampapathalu A. Nagarajaram, Centre for DNA
Fingerprinting and Diagnostics, Nacharam, Hyderabad 500076 India. Tel.:
91-40-27171502; Fax: 91-40-27155610; E-mail: han@cdfd.org.in.
 2006 by the Biophysical Society
0006-3495/06/12/4329/11 $2.00 doi: 10.1529/biophysj.106.085498
Biophysical Journal Volume 91 December 2006 4329–4339 4329
structural characteristics of FIRs are quite different in the MT
structures than theWT, and these altered structural properties
may not be conducive to the enzymatic function.
MATERIALS AND METHODS
Modeling of wild-type and mutant structures
The human CYP1b1 structure was modeled bymeans of comparative model-
ing procedures using the human CYP2c9 as the template. The sequence
alignment of CYP1b1 and CYP2c9 was carried out using the CLUSTALX
(http://www.ebi.ac.uk/clustalw) program and was further reﬁned manually
at some loop regions of the template. The academic version of MODELLER
v.4.0 (20) (http://salilab.org/modeller) installed on the SGI-O2 system was
used for model building. Of the 20 models generated by MODELLER, the
one with the best G-score of PROCHECK (21) and with the best VERIFY-
3D (22) proﬁle was subjected to energy minimization (EM) followed by MD
simulation for 300 ps (details of the protocol used are given in the following
sections). All the instantaneous structures generated were assessed for their
stereochemical quality using PROCHECK G-score, and the one with the
best G-score was selected as the representative of WT structure. The WT
structure was also further used as the starting structure to generate disease
MT structures by replacing WT residues with disease associated residues.
Overall, eight disease MT structures were generated corresponding to the
eight point mutations A-115P, M-132R, Q-144P, P-193L, E-229K, S-239R,
R-368H, and G-466D (18,23). The residue replacements were carried out
using the MUTATE_MODEL command of MODELLER.
Identiﬁcation of functionally important regions
CYPs are characterized by a highly conserved structural core divisible into
a-rich and b-rich domains comprising;14 helices and four to six b-sheets.
Functionally, CYP structure can also be characterized by means of ﬁve FIRs,
viz., the heme binding region (HBR), the substrate binding region (SBR), the
substrate access channel (SAC), the residues involved in charge relay, and
the surface region that binds to CYP reductase protein while receiving
electrons from it. For the purpose of this study some of these regions, viz.,
HBR, SBR, and SAC, were putatively identiﬁed as follows.
HBR
The HBR is deﬁned by a set of residues that are in contact with the heme
cofactor and such residues were identiﬁed as follows. The solvent accessible
surface area (SASA) of all residues in the protein with and without the heme
were calculated, and the residues that showed a decrease in SASA in the
presence of heme were denoted as those comprising the HBR.
SBR
To identify the SBR, the crystal structures of various CYP protein-ligand
complexes (Protein Data Bank (PDB) codes: 2cpp, 1pha, 6cp4, 1fag, 1e9x,
1egy, 1ea1, 1f4t) were used. The SBR residues in each structure were iden-
tiﬁed as those showing an increase in SASA upon the removal of the bound
ligand in the CYP-substrate complexes. The putative SBR residues in
CYP1b1 were then identiﬁed, as those found at the structurally equivalent
positions in CYP1b1 in the multiple structural alignment of CYP1b1 with
CYP-substrate complex structures.
SAC
The substrate access into the active site is thought to occur through an
opening between the F/G loop and the B9-helix. The pathway (SAC) from
outside to the active site of the protein is bounded by the F- and G-helices
and the B/C loop. Ludemann et al. (24,25) have studied the substrate access
pathway in P450cam and P450BM-3. They computationally demonstrated
that these structures are very likely to be involved in substrate entry and exit.
For our analysis we considered the SAC region as the residues comprising
the SAC entrance, viz., the F/G loop and B9-helix.
Molecular dynamics simulations
The GROMACS (26) program package (http://www.gromacs.org) adopting
the GROMOS96 force ﬁeld parameters was used for EM and MD simu-
lations. For the MD simulation studies, the structures were solvated (spc216
water representation) and Cl counterions (3,3,4,3,3,5,4,2, and 2 for WT,
A-115P,M-132R,Q-144P, P-193L, E-229K, S-239R, R-368H, andG-466D,
respectively) were added as required to neutralize the total charge of the
system by using the GENION option of GROMACS. The system consisted
of 41820, 41821, 41823, 41824, 41825, 41828, 41836, 41820, and 41832
atoms, respectively, in WT, A-115P, M-132R, Q-144P, P-193L, E-229K,
S-239R, R-368H, and G-466D. The solvated structures were energy mini-
mized using the steepest descent method, terminating when maximum force
is found smaller than 100 KJ/mol1/nm1. The energy-minimized structures
were subjected to position restrained dynamics for 25 ps keeping the whole
protein molecule ﬁxed and allowing only the water molecules to move to
equilibrate with respect to the protein structure. This followed dynamics
simulations of the full system (protein and water) without any positional
restraints.
All the simulations were performed in the NVT ensemble at constant
temperature (300 K) and pressure (1 bar) with a time step of 2 fs. The non-
bonded pair list was updated every ﬁve steps. The electrostatic interactions
were calculated using the particle mesh Ewald summation method (27).
During the simulation, constraints were applied on all bonds using the
LINCS (28) algorithm, with parameters LINCS-order-4 and LINCS-warn-
angle ¼ 30. Coordinates were saved at regular time intervals of every 1 ps.
Analysis of MD trajectories
Most of the structural properties, such as root mean-square deviation
(RMSD), root mean-square ﬂuctuation (RMSF), SASA, secondary structure
calculation, hydrogen bonds (Hbs), etc., were computed using the built-in
functions of GROMACS. Individual Hb interactions were calculated using
the HBPLUS (29) program. The volume of SBR was computed using the
program POCKET (30) with a water probe radius of 1.4 A˚. All the average
properties, including Hb interactions, were computed after the time of equi-
libration of the systems. The SWISS-PDB VIEWER (31) and PSA (32)
programs were used for superimpositions and solvent accessibility calcu-
lations, respectively.
RESULTS
Modeling CYP1b1 and its mutant forms
The experimentally (x-ray or NMR) determined structure of
the human CYP1b1 is not yet available, and therefore we
built a model by means of a comparative modeling pro-
cedure. A recently reported x-ray structure of CYP2c9 (33)
(1OG2) was used as the structural template. The sequence
alignment used for model building is shown in Fig. 1. The
alignment is characterized by some insertions and deletions
in the loop regions. Since the ﬁrst 49 residues from the
N-terminal end and the last 16 residues at the C-terminal
(residues 528–543) in CYP1b1 did not have corresponding
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equivalent regions in CYP2c9, the modeling was carried out
from the 50th to the 527th residue, followed by a rigorous
reﬁnement of the model by means of MD and EM (see the
Materials and Methods section for the protocol used). The
model (referred to as the wild-type and denoted by WT) has
92% of the residues in the most favored regions of the
Ramachandran Map with a PROCHECK’s (21) G-score
value of 0.21 and a satisfactory VERIFY-3D (22) proﬁle
(Supplementary Material). The model was used to identify
the structural parts which make up the HBR, the SBR, and
the SAC, i.e., the three functionally FIRs (see the Materials
and Methods section). The disease structure’s MTs were
modeled by replacing the side chains of the WT with the
PCG mutations. In total, eight MTs were obtained for the
eight PCG mutations.
Mapping of PCG mutations on the CYP structure
We examined the mutation sites in the WT vis a` vis the three
FIRs, viz., HBR, SBR, and SAC. It is observed that some of
the mutation sites are either among the residues comprising
the FIRs or near to them, whereas the others are far from any
of the FIRs (Supplementary Material). Mutations in spatially
close sites can be expected to exert an inﬂuence on FIRs.
Comparison of the WT and the MTs in the vicinity of the
mutations gave rise to the following observations.
A-115P
This mutation occurs within the B/B9 loop at the C-terminal
end of B-helix and is in close proximity to the HBR. A to P
substitution not only restricts conformational freedom at the
site but also precludes hydrogen-bonding interaction capa-
bility due to the absence of the amide hydrogen.
M-132R
This mutation site is in the HBR, in the loop connecting
B9- and C-helices. InWT the side chain of M extends into the
interior and packs well between I-helix (residues N-319–
Y-349) and one of the heme propionate groups. The N of
M-132 donates an Hb to D-326 of I-helix and accepts Hb
from G-135, W-141, and R-468, thus interconnecting the
I-helix, C-helix, and heme binding loop (HBL). Mutation
to R leads to congestion in the packing in the immediate
vicinity of the mutation site, thereby potentially harming the
H-bond interactions.
Q-144P
This mutation occurs in the middle of C-helix and is also
very close to the HBR. Mutation to P, a helix-breaking
residue, can potentially break the continuity of the C-helix.
The side chain of WT residue Q is in a polar environment
surrounded by the side chains of residues S-131, H-140,
R-314, and N-319 and makes Hbs with W-141 and A-147.
Apart from this Q-144 interacts with R-314 in the N-terminal
of I-helix, N-319, T-323 of I-helix, and S-131 of B9/C loop;
thus this site is located at the crucial junction interconnecting
helix I, helix C, and the B9/C-helix.
P-193L
This site is far away from any of the FIRs and is in the N-cap
position of E-helix. Replacement of P, which is a better
N-cap residue than L, can affect stability of the E-helix,
thereby affecting the packing in this region.
E-229K
This mutation occurs in the C-terminal of the F-helix in the
vicinity of the SBR. Substitution of E to K leads to a change
FIGURE 1 Sequence alignment of CYP1b1 (residues
50–527) with 1OG2 template (residues 30–490). The a-he-
lices (boxed regions) are named in alphabetical order (A–L).
The b-strands (boxed regions) are named using the sheet
number (S1–S5) in which they occur followed by the strand
number. The CHR and HBL regions are also represented by
boxed regions. The nomenclature for secondary structures
was adopted from the nomenclature generally followed in
CYP1b1 literature especially from Akarsu et al. (4). Minor
helices are indicated with a prime (A9, B9, F9, G9, and K9).
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from a negatively charged residue to a positively charged side
chain and this in turn affects the local charge distribution. This
mutation disturbs an important cluster of salt bridges. In WT,
R-194:::E-229, R-194:::D-333, and D-333:::K-512 form a
triangle of ionic bond interactions, holding I-helix with
F-helix and b-strand S3.2. Upon mutation, the R-194:::E-229
interaction is lost and has the potential to destabilize the other
ionic interactions.
S-239R
Position 239 is located in the F/G loop region and is an
exposed site and thus may not have severe consequences.
Nevertheless, since the region is close to the SAC, mutation
of S to R could affect the structure and dynamics of this
region. S makes main chain Hbs with T-234 and A-237 at the
C-terminal of F-helix, whereas its side chain makes a Hb
with T-256 and T-234.
R-368H
This is in between the J- and K-helices in an exposed loop,
and the consequence of this change is not immediately
apparent except that positively charged R is replaced by H,
whose charge state depends on its protonation state. In WT
R-368 interacts with G-365, D-367, V-363, Q-362, and
D-374. Upon mutation the bonds to D-367 and D-374 are
weakened. How this affects the conformation and function-
ality of the protein is not clear.
G-466D
This is located in the middle of the heme-binding loop (HBL)
and is a site involved in the interaction with reductase
protein. Presence of G is completely conserved in all CYP
proteins at this position. From the conformational point of
view, G is found in a turn and is accommodated well in the
limited volume between HBL and B-helix. This site being a
major docking area of the reductase protein, the mutation
from G to an acidic residue D may be undesirable for the
reductase binding since neutral/basic residues are preferred
in this reductase binding region (RBR). The presence of G is
completely conserved in all CYP proteins at this position.
MD simulation studies
Although the observations given above give some qualitative
aspects of the possible deleterious nature of the mutations, an
estimation of how these residue changes propagate into the
protein structure leading to a functionally disruptive effect
can be obtained by subjecting the MTs as well as the WT to
MD simulations. Hence, the WT and the MT structures were
subjected to MD simulations for 30 ns. The instantaneous
structures (snapshots) saved at every successive 1 ps from
the start of the simulation, totaling 30,000 for each structure,
were used for analysis of time evolution of various structural
properties analyzed in this study.
Overall structural changes
RMSD trajectories. The overall structural deviation of the
WT and the MTs from their starting structures during the
entire course of simulations is shown in Fig. 2. It should
be noted that the starting structures of WT and MTs were
identical except for the side chains of the residues at the
FIGURE 2 Trajectories of the overall
CaRMSDs (in angstroms) (black line) of
the WT and MT structures with respect
to the starting structure over 30,000 ps
MD simulation. The x axis represents
the simulation time in picoseconds. The
y axis represents RMSD in angstrom
units. Gray lines indicate the CaRMSD
trajectories calculated for only the sec-
ondary structures. This ﬁgure was pre-
pared using XMGRACE (50) (http://
plasmagate.weizmann.ac.il/Grace).
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mutation sites. The trajectories shown in Fig. 2 do not take
precisely the same course; all the structures initially evolve
rapidly during the ﬁrst 1.5–2 ns and seem to stabilize at
different times (Table 1). All further analyses were carried
out using the data collected after RMSD stabilization.
Whereas the all-Ca RMSD trajectories take long times for
stabilization, the trajectories of the secondary structures
(shown in gray in Fig. 2) quickly stabilize in all the struc-
tures. It may be noted that some of the RMSD trajectories
seem to stabilize for short periods before drifting to stable
structures. For example, in the case of A-115P and WT, both
the structures after an initial increase of RMSDs seem to
stabilize for some time (;5 ns), followed by a gradual drift
into another stabilized structure. An examination of the
structures revealed that some loop regions undergo slow
conformational transitions, during which time the RMSD
trajectories show slow drift-like variation. Owing to the fact
that structures simulated are from comparative modeling,
we discarded the early parts of stabilization and used only
those which seemed stabilized until the end of simulation.
The average value of the overall RMSD after stabilization is
;4.1 A˚ in WT, whereas in MTs it ranges from 3.4 A˚ to 3.9 A˚
(Table 1). The average values of RMSD after stabilization
for the secondary structures are ;2.9 A˚ in WT and between
2.8 A˚ to 3.4 A˚ in the MTs. Higher RMSDs of the secondary
structures in someMTs than theWT reﬂect relative structural
deviations occurring in the core of the MTs.
RMSF. The distribution of Ca RMSF values is shown in
Fig. 3. In the WT 54% of the residues have RMSF values
,1 A˚ (see Table 1). This could be considered the basal level
ﬂuctuation for the WT protein. All the MTs other than
A-115P have larger percentages of residues having RMSF
values .1 A˚ compared to the WT. Thus, on the whole, the
MTs are characterized by increased protein ﬂexibilities.
Similarly, the percentage of residues having RMSF .1 A˚ in
the protein core comprising secondary structural elements is
greater in MTs (except A-115P) than WT, thus indicating
that these MTs are associated with increases in ﬂexibilities in
some of the residues in the core region. The RMSF proﬁles
in Fig. 3 further illustrate residue-wise differences between
WT and MTs, which are conspicuously evident in terms of
peak heights that represent magnitudes of regional ﬂexibil-
ities. Comparison of these regional ﬂexibilities further
revealed characteristic decrease and increase in ﬂexibilities
in each of the MTs in certain loops, helices, and b-sheets as
given in Table 2.
Structural changes at the mutation sites. As mentioned
earlier substitutions of residues at the mutation sites are ex-
pected to bring out certain structural changes at the mutation
sites. To know the changes brought out by the mutations, we
computed the average values of the f, c dihedral angles and
number of times a given Hb interaction is observed during
simulations (referred to as the occupancy of Hb interaction)
at the mutation site in WT and MTs, and the results are
tabulated in Table 3.
From the table it can be seen that the G-466D mutation is
characterized by a major conformational change at the muta-
tion site compared to WT. The mutation site is marked by a
large change in the c angle from 106 (WT) to 1104
(MT), characterizing the ﬂipping of the peptide unit between
the residues 466 and 477. Concomitantly the Hb interactions
involving the C55O group at the mutation site have also
been severed. Compared to G-446D, the other mutations
have not led to such major conformational changes at their
respective sites. With regard to Hb interaction, absence or
presence of Hbs in the MTs has been determined by the
absence or presence of functional groups capable of forming
Hb interaction. For example, in A-115P, A inWT is involved
in two Hbs, of which one is formed by the amide hydrogen. P
in the MT was not involved in any such Hbs. The C55O of P
instead has formed Hb with a water molecule as it is on the
surface. In some cases, MTs are characterized by the forma-
tion of more numbers of Hb interactions, albeit with very low
occupancies.
TABLE 1 Average properties of WT and MT structures computed after RMSD stabilizations (T-stab)
RMSD (A˚) RMSF (A˚)
All ca Sec-str ca heme All ca Sec-str ca Cys-Fe (A˚) SBR (A˚3) SAC (A˚) Hbs
T-stab (ns) avg sd avg sd avg sd #1 A˚ .1 A˚ #1 A˚ .1 A˚ avg sd avg sd avg sd avg sd
WT 15 4.1 0.2 2.9 0.1 2.9 0.4 54 46 66 34 2.1 0.1 403.0 79.0 7.3 0.3 351.3 9.5
A-115P 15 3.7 0.2 2.8 0.2 4.5 0.3 60 40 73 27 2.9 0.1 392.2 110.7 8.3 0.3 342.2 9.5
M-132R 8 3.8 0.2 3.0 0.1 3.6 0.3 43 57 54 48 2.3 0.1 306.5 86.0 10.7 0.7 352.2 9.9
Q-144P 12 3.6 0.1 2.8 0.1 3.6 0.4 49 51 60 40 2.5 0.1 308.2 69.6 9.6 0.8 341.6 10.8
P-193L 7 3.8 0.1 3.4 0.1 2.3 0.3 41 59 53 47 3.3 0.4 610.0 172.6 7.9 1.2 347.0 10.0
E-229K 15 3.9 0.1 2.9 0.2 2.6 0.4 53 47 61 39 2.1 0.1 377.5 152.7 9.9 1.0 358.5 9.6
S-239R 8 3.8 0.2 3.0 0.2 2.6 0.4 35 65 43 57 1.9 0.1 355.3 106.4 7.7 0.4 355.1 9.7
R-368H 8 3.8 0.1 3.0 0.1 3.6 1.1 41 59 54 46 2.3 0.3 254.9 83.6 10.5 0.6 356.8 10.1
G-466D 5 3.4 0.2 2.9 0.1 2.3 0.3 51 49 61 39 2.2 0.1 747.1 295.3 9.2 0.4 342.3 9.5
‘‘RMSD’’ is the root mean-square deviation from the starting structure; ‘‘RMSF’’ is the average residue ﬂuctuations from their mean positions; ‘‘Cys-Fe’’ is
the coordination distance between the C470:sulfur atom and the Fe of heme; ‘‘SBR’’ is the volume of the putative SBR; ‘‘SAC’’ is the size of the substrate
access channel entrance formed by the structure’s F/G loop and the B9-helix; and ‘‘Hbs’’ are the average number of hydrogen bonds present in the structure.
For each property, the average (avg) and the standard deviations (sd) are given.
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Structural properties of the functionally important re-
gions.
a. HBR. The heme moiety is held in place by hydrophobic
and Hb interactions, formed by the HBL, C-helix,
b-strand S1.3, and B/B9 and B9/C loops (see Fig. 1 for the
deﬁnitions of secondary structures). The list of Hb in-
teractions and their occupancies in theWT andMTs dur-
ing simulations is given in Table 4. WT forms Hbs with
the surrounding structures with ;50% or more occu-
pancy. Comparatively all the MTs show a reduction or
complete absence of Hb interactions from one or many of
these structures, implying altered binding of the heme in
all the MTs than WT. It may be noted that decreased Hb
interactions in the case of MTs with the four structures
surrounding the propionates correlate with their increased
RMSF ﬂuctuations in those structures (Table 2). The
positional alteration of the heme in MTs is also indicated
by the Fe-Cys coordination. Only in E-229K is the
coordination bond length similar to that found in WT; in
all other MTs the coordination bond length is either
shorter or longer than that of the WT, with P-193L show-
ing the highest deviation (Table 1).We also computed the
RMSD for the heme with respect to its starting position.
The RMSD values (Table 1) indicate that the position
of the heme undergoes more deviation in all the MTs,
except P-193L and G-466D, compared to the WT.
b. SBR. We calculated the volume of the continuous void
over the hememoiety bounded by helices B9, I, F, andG,
b-strand S1.3, and B/C loop to represent the volume of
FIGURE 3 Residue-wise RMSF (in
angstroms) proﬁles of Ca atoms of the
WT and MT structures computed after
stabilization of the RMSD trajectories.
The x axis represents the residue num-
ber. The y axis represents RMSF in
angstrom units. The bars at the bottom
of the ﬁgure indicate the location of
a-helices (black) and b-strands (gray).
This ﬁgure was prepared using
XMGRACE.
TABLE 2 Regions (a-helices, b-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to
the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of[0.3 A˚
in at least 50% of its residues
Increase Decrease
A-115P D; S4.2, S3.2; C/D, B/B9, E/F, G/H, H/I, J/K, K9/L9 B9, F; D/E, K/K9
M-132R B, H; S1.1, S1.2, S2.1, S2.2, S4.2; B/B9, B9/C, G/H, H/I, K9/L9, CHR, HBL, F/G F; C/D, D/E, E/F, J/K, K/K9
Q-144P B9, G, H; S4.1; B/B9, G/H, H/I, HBL C/D, D/E, E/F, J/K
P-193L B9, D, F, G; S1.1, S1.2, S4.1, S4.2; B/B9, B9/C, F/G, G/H, L9/L, CHR, HBL C/D, D/E, H/I, J/K, K/K9
E-229K G; S4.1, S3.1, S3.2; F/G J; C/D, D/E, E/F, H/I, J/K
S-239R D, E; S5.1; B9/C, E/F, J/K, K9/L9, HBL C/D, D/E
R-368H B, B9, E, K9; S1.2; B/B9, G/H, K9/L9, HBL F; C/D, D/E, E/F, J/K, L9/L
G-466D D, I, K9; H/I, K9/L9 B9, F; C/D, D/E, E/F, L9/L
See Fig. 1 for the deﬁnitions of a-helices and b-sheets. Loops are denoted by their ﬂanking helices. HBL denotes heme binding loop; CHR denotes charge
relay region.
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the SBR. Although the volume measured this way may
be more than the actual volume occupied by any hypo-
thetical substrate, it nevertheless gives a convenient
representation of SBR for comparison purposes. In WT,
on average, the volume is ;403 A˚3 (Table 1) and the
value hardly ﬂuctuates. The MTs R-368H, M-132R,
Q-144P, S-239R, E-229K, andA-115P show a reduction
in the size of their SBRs, whose volumes are, respec-
tively, 63%, 76%, 76%, 88%, 94%, and 97% of that of
WT. In the case of P-193L and G-466D the volumes of
SBR have increased to 151% and 185%, respectively,
of that of the WT. This result indicates that the MTs are
characterized by a distorted substrate-binding pocket,
either smaller or larger than that found in the WT.
TABLE 3 Average f, c dihedral angle conformations and the occupancies of the Hb interactions involving the mutation
positions in the WT and the MTs
Wild-type MUTANT
MT site f c Hb Occ f c Hb Occ
A-115P 117.1 23.9 [HBL] 468ARG(NH1):::115ALA(O)[B/B9] 91 81.2 30.9
[B/B9] 115ALA(N):::404THR(OG1)[S1.3] 75
M-132R 106.8 71.8 [B9/C] 135GLY(N):::132MET(O) [B9/C] 57 71.5 50.9 [HBL] 468ARG(NH1):::132ARG(O) [B9/C] 74
[HBL] 468ARG(NH2):::132MET(O) [B9/C] 31 [B9/C] 132ARG(N):::326ASP(OD1) [I] 34
[B9/C] 132MET(N):::326ASP(OD1)[I] 15 [HBL] 468ARG(NH2):::132ARG(O) [B9/C] 31
[B9/C] 132MET(N):::326ASP(OD2)[I] 10 [B9/C] 132ARG(N):::326ASP(OD2) [I] 22
[B9/C] 132ARG(NE):::326ASP(OD1) [I] 16
[B9/C] 132ARG(NH2):::144GLN(OE1) [C] 16
[B9/C] 132ARG(NH2):::323THR(OG1) [I] 13
[B9/C] 132ARG(NE):::322ALA(O) [I] 12
[B9/C] 132ARG(NH1):::322ALA(O) [I] 11
[B9/C] 132ARG(NE):::322ASP(OD2) [I] 10
[B9/C] 132ARG(NH1):::323THR(OG1) [I] 10
Q-144P 58.6 46.7 [C]148ALA(N):::144GLN(O) [B9/C] 98 54.8 46.5 [E]148ALA(N):::144PRO(O)[C] 99
[C]144GLN(N):::140HIS(O)[C] 92 [E]147ALA(N):::144PRO(O)[C] 10
[I]323THR(OG1):::144GLN(OE1)[C] 26
[C]144GLN(NE2):::131SER(OG) [B9/C] 15
[I]319ASN(ND2):::144GLN(OE1)[C] 15
[C]144GLN(NE2):::140HIS(O)[C] 14
P-193L 58.2 37.2 [E]197THR(N):::193PRO(O)[E] 97 57.7 39.7 [E]197THR(N):::193LEU(O)[E] 91
[E]196LEU(N):::193PRO(O)[E] 40 [E]193LEU(N):::516PHE(O)[S5.2] 72
[E]196LEU(N):::193LEU(O)[E] 32
[E]197THR(OG1):::193LEU(O)[E] 12
[E]193LEU(N):::515SER(OG) [S3.2] 10
E-229K 57.7 49.7 [F]229GLU(N):::225LEU(O)[F] 94 58.8 47.8 [F]229LYS(N):::225LEU(O)[F] 95
[F]233ARG(N):::229GLU(O)[F] 60 [F]233ARG(N):::229LYS(O)[F] 77
[F]234THR(N):::229GLU(O)[F] 16 [F]229LYS(N):::226SER(O)[F] 14
[F]229GLU(N):::226SER(O)[F] 15
[F]232GLY(N):::229GLU(O)[F] 10
S-239R 64.1 40.9 [F]243VAL(N):::239SER(O)[F/G] 79 43 46.2 [F]243VAL(N):::239ARG(O)[F/G] 94
[F/G]239SER(N):::234THR(O)[F] 23 [F/G]239ARG(NH2):::234THR(O)[F] 40
[F/G]239SER(N):::235VAL(O)[F] 20 [F/G]239ARG(NH2):::233ARG(O)[F] 26
[F/G]242ASP(N):::239SER(O)[F/G] 14 [F/G]239ARG(NH2):::256THR(O)[G] 21
[F/G]239ARG(NH1):::233ARG(O)[F] 17
[F/G]239ARG(NE):::255ARG(O)[F/G] 15
[F/G]242ASP(N):::239ARG(O)[F/G] 12
[F/G]239ARG(NE):::234THR(O)[F] 11
[F/G]239ARG(N):::236GLY(O)[F] 10
[F/G]239ARG(NH1):::255ARG(O)[F/G] 10
R-368H 78.9 96.3 [J/K]365GLY(N):::368ARG(O)[J/K] 83 99.5 116.7 [J/K]368HIS(N):::365GLY(O)[J/K] 43
[J/K]368ARG(NH1):::362GLN(O)[J] 14 [L]489HIS(NE2):::368HIS(O)[J/K] 40
[J/K]365GLY(N):::368HIS(O)[J/K] 32
[J/K]368HIS(NE2):::374ASP(OD1)[J/K] 10
[J/K]368HIS(NE2):::374ASP(OD2)[J/K] 10
G-466D 101.8 106 [HBL]469ARG(NE):::466GLY(O)[HBL] 30 53.7 104.1 [HBL]469ARG(NH1):::466ASP(OD2) [HBL] 10
[HBL]469ARG(NH1):::466GLY(O)[HBL] 17
[HBL]469ARG(NH2):::466GLY(O)[HBL] 15
[HBL]466GLY(N):::528HEM(O1A)[HEME] 10
‘‘Occ’’ denotes the Hb occupancy percentage. Only Hbs with occupancies $10 are shown. For each Hb interaction, the secondary structures/loop regions
involved in the interaction are indicated within square brackets.
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c. SAC. The catalytic site of CYP1b1 or the SBR is not
directly accessible from the surface of the protein.
Thermal motion pathway analysis (34) in p450cam had
revealed the existence of three potential substrate entry/
exit pathways (denoted by pw1, pw2, and pw3). Random
expulsion MD (REMD) ligand egress (24,25) trajecto-
ries further revealed three subpathways (a, b, and c) in
the pathway pw2. Pathway pw2a, comprising the F/G
loop and the B9-helix, has been found to be a common
pathway among the p450s (24,25,35–40), and hence
we monitored the size of the opening between the F/G
loop and the B9-helix during the entire period of
simulation (Supplementary Material). In the WT the
average distance is ;7 A˚ and seems to be stabilized by
the Hb R-124::L-247 formed between the F/G loop and
the B9-helix. An earlier study involving ‘‘REMD’’
simulations (24) had revealed the breakage and
formation of similar Hb interactions between the F/G
loop and the B9-helix. The MTs A-115P and S-239R
also show hydrogen-bonding patterns similar to WT. In
correlation, the SAC size of A-115P and S-239R is
similar to WT. Whereas the MTs M-132R, E-229K,
R-368H, and G-466D show a complete absence of
Hbs between the F/G loop and the B9-helix, the MTs
Q-144P and P-193L have irregular patterns of Hbs.
Accordingly, in these MTs the conformation of SAC is
wider and associated with noticeably large ﬂuctuations.
DISCUSSION
The CYP1b1 model
Modeling studies reported earlier (11,16) have used the
bacterial CYPs (CYP102, CYP108, and CYPc17) as struc-
tural templates. Of these templates, CYP102 (p450BM-3)
was considered a good template for modeling eukaryotic
CYPs because it shares more features in common with the
eukaryotic CYPs than the other bacterial CYPs. After elu-
cidation of the ﬁrst mammalian CYP structure, viz., CYP2c5
(33), Shimada and co-workers (41) used it as a template to
model CYP1b1 for their study on the binding mode of se-
lected substrates with regard to the effects of allelic variants
of CYP1b1 on their metabolism. Recently the structure of
human CYP2c9 (PDB-CODE: 1OG2) (42) was reported,
and it has a sequence identity of 31.5% with CYP1b1. Given
the fact that CYPs within a species are expected to have more
structural similarity, CYP2c9 has been used as the template
in this study. The model of CYP1b1 reported in this study
can be considered better than the earlier reported models
because of the following reasons. The loop region between
the F- and G-helices, a FIR, has been modeled better due to
good correspondence of alignment in the template. Tem-
plates used for modeling in earlier modeling studies lacked
proper structural information for this region because of its
highly variable nature and because some templates lacked
coordinate data. Importantly, the region in CYP2c9 has short
helices F9 and G9, a human-speciﬁc CYP structural feature
not observed in bacterial and other mammalian CYP struc-
tures (42). Furthermore, the three-dimensional (3D) model
obtained from MODELLER was further subjected to rigor-
ous reﬁnement by a combination of EM and short MD to
relieve stereochemical strains.
Deleterious nature of the mutations
The detailed structural analysis by means of MD simulations
in this study conﬁrms some of our earlier speculations about
the effects of some of these mutations (19). The average
structural properties, though, indicate similarity of the
overall fold of MTs and WT. The precise differences in the
RMSD trajectories, which indicate the differences in the path
of transition of structures from the starting conformation to
their ﬁnal states despite the initial structures being identical
(except at the mutation sites), clearly speaks of the inﬂuence
of residue substitutions on the dynamics of the protein. The
RMSF data indicate that mutations are characterized by a
subtle but signiﬁcant increase in the ﬂexibility of the mole-
cule. Further, the individual MTs have speciﬁc regions of
increased or decreased ﬂuctuations compared to WT, some
of these located at spatially distant sites and forming part of
FIRs.
TABLE 4 Occupancies (in %) of Hbs between ‘‘heme’’ and protein residues from structures surrounding heme in the WT and
MTs; only occupancies $5% are shown
B/B9 loop B9/C loop C-helix b-strand S1.3 HBL
117 135 137 141 145 398 399 401 464 465 466 467 468 469 470 471
WT 48 – – 84 73 31 48 – 41 – 17 10 94 22 – –
A-115P 24 – – – 25 – – – – – 97 – – 46 – –
M-132R – – – 72 18 – – 55 – – 48 10 67 46 – –
Q-144P – – 54 – 32 – – – 61 36 61 37 74 74 – –
P-193L 27 – – – 88 – – – 89 – – – 71 – – 18
E-229K 99 – – 79 16 – – 96 61 – 96 83 99 20 – –
S-239R 82 13 – – 19 – – 28 94 – 37 – 93 71 – –
R-368H 47 – 87 – – – – – – 27 70 53 79 30 – –
G-466D 98 – 10 – 77 – – 66 91 – – – – 59 – –
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It is also observed that mutations have an effect on the
integrity of the active site pocket. From a functional point of
view the active site regions of enzymes are fairly rigid
structures, allowing for speciﬁc interactions of functional
groups of the enzyme and substrate. Any change in the
structure of the active site region can affect the substrate
binding and functional interactions between the substrate and
the enzyme. The volume of the SBR gives a measure of the
disruptive effect due to mutations. As revealed in this study,
the volume of the substrate-binding pocket is different in
all MTs except A-115P compared to WT. In P-193L and
G-466D the volumes of SBRs are larger than the WT,
whereas in the other ﬁve MTs (M-132R, Q-144P, E-229K,
S-239R, and R-368H) the SBRs are smaller in volume than
theWT. A-115P, which shows a severe effect on HBR, seems
to have no effect on SBR. In terms of the most affecting mu-
tation on SBR, G-466D stands out distinctly.
The MTs also reveal changes in the conformation and
dynamics of the SAC region wherein in all the MTs the
size of the channel opening is greater than that of WT. More-
over, in some of the MTs (M-132R, Q-144P, P-193L,
and E-229K) the SAC ﬂutters irregularly, most severely in
P-193L (Supplementary Material), during the course of the
entire simulation, probably indicating disruption of substrate
recognition and also its accessibility.
We also examined the correlation between theMTs and the
WT for residue-wise Hb occupancies and the RMSFs, both of
which give a measure of the nature of the 3D fold of the
protein. It was found that MTs Q-144P, S-239R, R-368H,
E-229K, and A-115P show poor correlation (Cij # 0.7) for
Hbs, whereas M-132R, E-229K, P-193L, R-368H, Q-144P,
and G-466D show poor correlation for RMSFs. (Table 5).
Furthermore, the extent of overall deviations of all the aver-
age properties of the MTs compared to the WT place the
MTs Q-144P, G-466D, R-368H, A-115P, P-193L, M-132R,
E-229K, and S-239R in descending order of deleteriousness
(Table 1). But the deleteriousness observed in a speciﬁc FIR
could be more severe in some MTs than others. For example,
the Cys-heme coordination bond distance can be used to
quantify the extent of structural deviation occurring in the
HBR in MTs than the WT. In P-193L, this distance is
;3.28 A˚, which is more than the usual coordination bonding
distance in CYPs (;2 A˚). InMTs A-115P, Q-144P,M-132R,
R-368H, and G-466D the distance is a little over the WT
ranging between 2.2 A˚ and 2.9 A˚. E-229K exhibits the same
distance as that of WT (2.1 A˚), whereas S-239R shows 1.85
A˚. Thus HBR, from the Cys-heme coordination bond point of
view, is affected severely by P-193L mutation and less
severely by A-115P than the other mutations. Other MTs
having coordination distance between 1.85 A˚ and 2.55 A˚ may
have proper heme binding. The Cys-heme distance roughly
correlates with the RMSD of the heme cofactor from initial
conformation. The other indicator of deleteriousness at the
HBR, viz., RMSD of heme from its initial conformation,
indicates A-115P as the most deleterious mutation.
Generally, loss of protein function can happen when key
residue substitutions occur in catalytic/substrate binding
sites. However, several disease-causing mutations have been
reported which do not occur in catalytic/substrate binding
sites. It is argued that such mutations manifest their deleteri-
ous effects by bringing in changes in structural characteris-
tics such as a change in surface charge distribution, disruption
of packing in protein core regions, etc. In general, any amino
acid substitution, whether pathogenic or nonpathogenic, has
some impact on the protein structure. The extent of impact is
dependent on the position and the nature of the amino acid
that is replaced, as well as on the newly introduced amino
acid. Some replacements are well accommodated in the pro-
tein structure either with or without any structural changes in
the protein such as rearrangements in packing of secondary
structural elements in the core (43–45). In the case of the
pathogenic mutations investigated in this study, it has been
found that they can be accommodated into the protein struc-
ture but are associated with some structural changes that are
functionally signiﬁcant.
Sunyaev et al. (46) as well as Wang and Moult (47) have
proposed a few criteria to qualitatively judge whether an
amino acid mutation can be deleterious or not. Accordingly,
mutations M-132R, Q-144P, E-229K, S-239R, R-368H, and
G-466D lead to a change in electrostatics and hydrophobic-
ity; mutation Q-144P introduces the helix-breaking residue P
in the middle of C-helix. A multiple sequence alignment of
p450 sequences was taken from the PFAM database to study
the proﬁle of amino acids at the mutation sites. Many of the
mutation sites have the WT allele occurring at a greater
frequency than the MT residue. Positions 466 and 368 seem
especially to be highly conserved among all the p450s. Other
mutation positions, though not very much conserved among
all p450s, are more speciﬁc to CYP1b1s. Mutation site 193
has a higher proportion of mutated residue L in general but
the proportion of P increases as we consider speciﬁcally
CYP1b1s. This might mean that CYP1b1 has adapted more
speciﬁcally to P rather than L, and P might be important for
its structural integrity. Positions 132 and 144 are not com-
pletely conserved among the three CYP1b1 members. But it
is clear that none of the MT residues occur among the three
mammalian CYP1b1 members, as well as other p450 pro-
teins except for mutations P-193L and E-229K and S-239R,
TABLE 5 Correlation coefﬁcients (Cij) between WT and MTs,
for the Hb occupancies and residue-wise Ca RMSF proﬁles
WT versus MT Hbs (Cij) RMSF (Cij)
A-115P 0.66 0.76
M-132R 0.71 0.42
Q-144P 0.55 0.66
P-193L 0.73 0.56
E-229K 0.61 0.50
S-239R 0.57 0.72
R-368H 0.58 0.50
G-466D 0.76 0.68
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indicating the incompatibility of the MT residues for these
positions in all CYPs in general. For P-193L, E-229K, and
S-239R, though some proteins do have the MT residues,
when it comes to the case of CYP1b1s the MT residues are
no longer represented, indicating the structural speciﬁcity of
CYP1b1 for the WT residues.
Severity of disease manifestation versus extent
of structural disruption of MTs
Panicker et al. (48) have performed genotype-phenotype
correlation studies and have indicated severity of disease
manifestation for some of the PCG mutations found in the
Indian population. They have reported, based on the clinically
observed phenotype, the percentages of severe phenotypes in
the Indian population associated with various mutations in
at least one eye. They are P-193L (62.5%), E-229K (80%),
and R-368H (72%). These percentages represent the cases in
which severe disease phenotypes were observed, but they do
not really compare the extent of disease severity associated
with each mutation. Further, incomplete penetrance of the
PCG mutations (49) makes the assessment of the deleteri-
ousness of each mutation difﬁcult. The MD simulation data
presented here on the disruptive effect on speciﬁc FIRs could
be validated with experimental evidence and then effectively
used for disease prognosis.
The role of molecular dynamics in revealing the
deleterious nature of disease mutations
A previous homology modeling study on CYP1b1 (11)
suggested that some of the mutations (W-57C, G-61E,
G-365W, P-379L, R-390H, E-387K, P-437L, and R-469W)
might disrupt either the hinge region or the conserved core of
the protein. In another study, homology modeling of MT
forms of CYP1b1 indicated that one (R-444Q) out of the four
(D-192V, A-330F, V-364M, and R-444Q) missense muta-
tions in the protein caused signiﬁcant structural changes
whereas the remaining were structurally neutral (16).
Although qualitative analysis and modeling studies give
clues about the possible effects of disease-causing mutations
in proteins, it remains still intriguing how precisely residue
changes in sites other than FIRs can bring about changes in
protein structure, which in turn have deleterious effects on
protein function. In this context, our study becomes impor-
tant. Further it also shows that MD simulation has vast
potential to elucidate the structure-function relationships in
greater detail to precisely understand the function impeding
mechanisms. The current MD simulation study on CYP1b1
gives some clues about the possible underlying structural
disruptions leading to loss of function due to disease muta-
tions. It can be postulated in the context here that the PCG
MT proteins carrying the pathogenic mutations fold into a
WT-like structure, but with changed structural properties,
which are detrimental to the WT-like function. Changes in
WT-like structural properties may lead to impairment of one
or more of the following: substrate access and binding
abilities, interaction with the reductase, electron transfer abi-
lity, and efﬁcient binding of heme. Any such functional im-
pairment can potentially cause pathogenicity. In vitro testing
of these MT forms for their catalytic activity on common
CYP1b1 substrates is currently being carried out which can
validate the inferences made from this study.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
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